Plaque-neutralizing antibody to BA.2.12.1, BA.4 and BA.5 in individuals with three doses of BioNTech or CoronaVac vaccines, natural infection and breakthrough infection.
COVID-19
Omicron, Neutralization
SARS-CoV-2
Vaccine
Journal
Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology
ISSN: 1873-5967
Titre abrégé: J Clin Virol
Pays: Netherlands
ID NLM: 9815671
Informations de publication
Date de publication:
11 2022
11 2022
Historique:
received:
15
07
2022
revised:
22
08
2022
accepted:
26
08
2022
pubmed:
10
9
2022
medline:
12
10
2022
entrez:
9
9
2022
Statut:
ppublish
Résumé
BA.2.12.1, BA.4 and BA.5 subvariants of SARS-CoV-2 variant-of-concern (VOC) Omicron (B.1.1.529) are spreading globally. They demonstrate higher transmissibility and immune escape. Determine BA.2.12.1, BA.4 and BA.5 virus plaque reduction neutralization test (PRNT) antibody titres in individuals recently vaccinated with BNT162b2 (n = 20) or CoronaVac (n = 20) vaccines or those convalescent from ancestral wild- type (WT) SARS-CoV-2 (n = 20) or BA.2 infections with (n = 17) or without (n = 7) prior vaccination. Relative to neutralization of the WT virus, those vaccinated with BNT162b2 had 4.8, 3.4, 4.6, 11.3 and 15.5-fold reductions of geometric mean antibody titres (GMT) to BA.1, BA.2, BA.2.12.1, BA.4 and BA.5 viruses, respectively. Similarly, those vaccinated with CoronaVac had 8.0, 7.0, 11.8, 12.0 and 12.0 fold GMT reductions and those with two doses of CoronaVac boosted by BNT162b2 had 6.1, 6.7, 6,3, 13.0 and 21.2 fold GMT reductions to these viruses, respectively. Vaccinated individuals with BA.2 breakthrough infections had higher GMT antibody levels vs. BA.4 (36.9) and BA.5 (36.9) than unvaccinated individuals with BA.2 infections (BA.4 GMT 8.2; BA.5 GMT 11.0). BA.4 and BA.5 subvariants were less susceptible to BNT162b2 or CoronaVac vaccine elicited antibody neutralization than subvariants BA.1, BA.2 and BA.2.12.1. Nevertheless, three doses BNT162b2 or booster of BNT162b2 following two doses of CoronaVac elicited detectable BA.4 and BA.5 neutralizing antibody responses while those vaccinated with three doses of CoronaVac largely fail to do so. BA.2 infections in vaccinated individuals led to higher levels of BA.4 or BA.5 neutralizing antibody compared to those who were vaccine-naive.
Sections du résumé
BACKGROUND
BA.2.12.1, BA.4 and BA.5 subvariants of SARS-CoV-2 variant-of-concern (VOC) Omicron (B.1.1.529) are spreading globally. They demonstrate higher transmissibility and immune escape.
OBJECTIVES
Determine BA.2.12.1, BA.4 and BA.5 virus plaque reduction neutralization test (PRNT) antibody titres in individuals recently vaccinated with BNT162b2 (n = 20) or CoronaVac (n = 20) vaccines or those convalescent from ancestral wild- type (WT) SARS-CoV-2 (n = 20) or BA.2 infections with (n = 17) or without (n = 7) prior vaccination.
RESULTS
Relative to neutralization of the WT virus, those vaccinated with BNT162b2 had 4.8, 3.4, 4.6, 11.3 and 15.5-fold reductions of geometric mean antibody titres (GMT) to BA.1, BA.2, BA.2.12.1, BA.4 and BA.5 viruses, respectively. Similarly, those vaccinated with CoronaVac had 8.0, 7.0, 11.8, 12.0 and 12.0 fold GMT reductions and those with two doses of CoronaVac boosted by BNT162b2 had 6.1, 6.7, 6,3, 13.0 and 21.2 fold GMT reductions to these viruses, respectively. Vaccinated individuals with BA.2 breakthrough infections had higher GMT antibody levels vs. BA.4 (36.9) and BA.5 (36.9) than unvaccinated individuals with BA.2 infections (BA.4 GMT 8.2; BA.5 GMT 11.0).
CONCLUSIONS
BA.4 and BA.5 subvariants were less susceptible to BNT162b2 or CoronaVac vaccine elicited antibody neutralization than subvariants BA.1, BA.2 and BA.2.12.1. Nevertheless, three doses BNT162b2 or booster of BNT162b2 following two doses of CoronaVac elicited detectable BA.4 and BA.5 neutralizing antibody responses while those vaccinated with three doses of CoronaVac largely fail to do so. BA.2 infections in vaccinated individuals led to higher levels of BA.4 or BA.5 neutralizing antibody compared to those who were vaccine-naive.
Identifiants
pubmed: 36081282
pii: S1386-6532(22)00205-0
doi: 10.1016/j.jcv.2022.105273
pmc: PMC9428331
pii:
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
COVID-19 Vaccines
0
Viral Vaccines
0
BNT162 Vaccine
N38TVC63NU
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
105273Subventions
Organisme : NIAID NIH HHS
ID : U01 AI151810
Pays : United States
Informations de copyright
Copyright © 2022. Published by Elsevier B.V.
Déclaration de conflit d'intérêts
Declaration of Competing Interest None of the authors had competing financial or non-financial interests.
Références
Cell. 2022 Jul 7;185(14):2422-2433.e13
pubmed: 35772405
Science. 2022 Aug 19;377(6608):890-894
pubmed: 35857529
Nature. 2022 Mar;603(7902):679-686
pubmed: 35042229
Nature. 2022 Feb;602(7898):654-656
pubmed: 35016196
Nature. 2022 Aug;608(7923):593-602
pubmed: 35714668
Nature. 2020 Jul;583(7818):834-838
pubmed: 32408338
Euro Surveill. 2022 May;27(18):
pubmed: 35514306
Nat Med. 2021 Jul;27(7):1205-1211
pubmed: 34002089
Cell Host Microbe. 2022 Sep 14;30(9):1231-1241.e6
pubmed: 35921836
Nature. 2022 Aug;608(7923):603-608
pubmed: 35790190
N Engl J Med. 2022 Jul 7;387(1):86-88
pubmed: 35731894
Nat Med. 2022 Mar;28(3):486-489
pubmed: 35051989
EClinicalMedicine. 2021 Nov;41:101174
pubmed: 34746725
Lancet Infect Dis. 2022 Apr;22(4):483-495
pubmed: 34890537
Lancet Infect Dis. 2022 Oct;22(10):1435-1443
pubmed: 35850128
Proc Natl Acad Sci U S A. 2020 Mar 31;117(13):7001-7003
pubmed: 32165541
N Engl J Med. 2021 Dec 9;385(24):e84
pubmed: 34614326
Nat Med. 2022 Sep;28(9):1785-1790
pubmed: 35760080
N Engl J Med. 2022 Jul 7;387(1):21-34
pubmed: 35704396
Nat Commun. 2022 Aug 10;13(1):4686
pubmed: 35948557